APO Research
Talk to an analyst

APO RESEARCH · REPORT

Alpha 1 Antitrypsin Deficiency Treatment

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

Selected research

Market Analysis & Forecast

Global Alpha 1 Antitrypsin Deficiency Treatment Market Analysis and Forecast 2026-2032

29 December 2025196 pages

Choose your research edition.

Industry ResearchAlpha 1 Antitrypsin Deficiency Treatment Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Alpha 1 Antitrypsin Deficiency Treatment Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Alpha 1 Antitrypsin Deficiency Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Alpha 1 Antitrypsin Deficiency Treatment Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Alpha 1 Antitrypsin Deficiency Treatment Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

Alpha-1 antitrypsin deficiency (A1AD) is a hereditary disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT) which is found in the blood. This deficiency may predispose an individual to several illnesses and most commonly manifests as chronic obstructive pulmonary disease (including bronchiectasis) and liver disease (especially cirrhosis and hepatoma), or more rarely, as a skin condition called panniculitis. A1AD is also more frequent among individuals with Wegener’s granulomatosis, now called polyangiitis with granulomatosis. A deficiency of A1AT allows substances that break down proteins (so-called proteolytic enzymes) to attack various tissues of the body. The attack results in destructive changes in the lungs (emphysema) and may also affect the liver and skin. Alpha-1 antitrypsin is ordinarily released by specialized, granules within a type of white blood cells (called neutrophils or polymorphonuclear leukocytes) in response to infection or inflammation. Deficiency of alpha-1 antitrypsin results in unbalanced (i.e., relatively unopposed) rapid breakdown of proteins (protease activity), especially in the supporting elastic structures of the lungs. Over years, this destruction can lead to progressive emphysema and is accelerated by smoking, some occupational exposures, and likely by other genetic modifiers of this risk which remain incompletely understood.

Global players of Alpha 1 Antitrypsin Deficiency Treatment include Pfizer, GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Takeda, Baxter, Grifols, CSL Behring and Kamada Ltd, etc. Top five players occupy for share about 28%. United States is the largest market, with a share about 37%, followed by European Union and China. In terms of product, Augmentation Therapy is the largest segment, with a share over 44%.

Report Includes

Read the full market overview

This report presents an overview of global market for Alpha 1 Antitrypsin Deficiency Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Alpha 1 Antitrypsin Deficiency Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Alpha 1 Antitrypsin Deficiency Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Alpha 1 Antitrypsin Deficiency Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Alpha 1 Antitrypsin Deficiency Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Alpha 1 Antitrypsin Deficiency Treatment revenue, projected growth trends, production technology, application and end-user industry.

Alpha 1 Antitrypsin Deficiency Treatment Segment by Company

Pfizer

GlaxoSmithKline

AstraZeneca

Boehringer Ingelheim

Teva Pharmaceutical Industries

Takeda

Baxter

Grifols

CSL Behring

Kamada Ltd

Chiesi Pharmaceuticals

Kedrion Group

Vertex Pharmaceuticals

ProMetic Life Sciences

Alpha 1 Antitrypsin Deficiency Treatment Segment by Indication

Augmentation Therapy

Cystic Fibrosis(CF)

Non-CF Bronchiectasis(NCFB)

Diabetes

Other

Alpha 1 Antitrypsin Deficiency Treatment Segment by End Users

COPD

Cystic Fibrosis(CF)

Non-CF Bronchiectasis(NCFB)

Diabetes

Alpha 1 Antitrypsin Deficiency Treatment Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha 1 Antitrypsin Deficiency Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Alpha 1 Antitrypsin Deficiency Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha 1 Antitrypsin Deficiency Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Alpha 1 Antitrypsin Deficiency Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Alpha 1 Antitrypsin Deficiency Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Alpha 1 Antitrypsin Deficiency Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication (US$ Million), 2021 VS 2025 VS 2032 Table 2. Augmentation Therapy Major Player Table 3. Cystic Fibrosis(CF) Major Player Table 4. Non-CF Bronchiectasis(NCFB) Major Player Table 5. Diabetes Major Player Table 6. Other Major Player Table 7. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by End Users (US$ Million), 2021 VS 2025 VS 2032 Table 8. COPD Major Player Table 9. Cystic Fibrosis(CF) Major Player Table 10. Non-CF Bronchiectasis(NCFB) Major Player Table 11. Diabetes Major Player Table 12. Alpha 1 Antitrypsin Deficiency Treatment Industry Trends Table 13. Alpha 1 Antitrypsin Deficiency Treatment Industry Drivers Table 14. Alpha 1 Antitrypsin Deficiency Treatment Industry Opportunities and Challenges Table 15. Alpha 1 Antitrypsin Deficiency Treatment Industry Restraints Table 16. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2021-2026) Table 19. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region (2027-2032) Table 21. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2021-2026) Table 23. Global Alpha 1 Antitrypsin Deficiency Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Alpha 1 Antitrypsin Deficiency Treatment Key Players Headquarters & Area Served Table 25. Global Alpha 1 Antitrypsin Deficiency Treatment Players, Product Type & Application Table 26. Global Alpha 1 Antitrypsin Deficiency Treatment Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Alpha 1 Antitrypsin Deficiency Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2021-2026) & (US$ Million) Table 31. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2027-2032) & (US$ Million) Table 32. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2021-2026) Table 33. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2027-2032) Table 34. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2021-2026) & (US$ Million) Table 36. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2027-2032) & (US$ Million) Table 37. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2021-2026) Table 38. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2027-2032) Table 39. Pfizer Company Information Table 40. Pfizer Business Overview Table 41. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 43. Pfizer Recent Development Table 44. GlaxoSmithKline Company Information Table 45. GlaxoSmithKline Business Overview Table 46. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 48. GlaxoSmithKline Recent Development Table 49. AstraZeneca Company Information Table 50. AstraZeneca Business Overview Table 51. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 53. AstraZeneca Recent Development Table 54. Boehringer Ingelheim Company Information Table 55. Boehringer Ingelheim Business Overview Table 56. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 58. Boehringer Ingelheim Recent Development Table 59. Teva Pharmaceutical Industries Company Information Table 60. Teva Pharmaceutical Industries Business Overview Table 61. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 63. Teva Pharmaceutical Industries Recent Development Table 64. Takeda Company Information Table 65. Takeda Business Overview Table 66. Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Takeda Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 68. Takeda Recent Development Table 69. Baxter Company Information Table 70. Baxter Business Overview Table 71. Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Baxter Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 73. Baxter Recent Development Table 74. Grifols Company Information Table 75. Grifols Business Overview Table 76. Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Grifols Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 78. Grifols Recent Development Table 79. CSL Behring Company Information Table 80. CSL Behring Business Overview Table 81. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 83. CSL Behring Recent Development Table 84. Kamada Ltd Company Information Table 85. Kamada Ltd Business Overview Table 86. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 88. Kamada Ltd Recent Development Table 89. Chiesi Pharmaceuticals Company Information Table 90. Chiesi Pharmaceuticals Business Overview Table 91. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 92. Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 93. Chiesi Pharmaceuticals Recent Development Table 94. Kedrion Group Company Information Table 95. Kedrion Group Business Overview Table 96. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 97. Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 98. Kedrion Group Recent Development Table 99. Vertex Pharmaceuticals Company Information Table 100. Vertex Pharmaceuticals Business Overview Table 101. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 102. Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 103. Vertex Pharmaceuticals Recent Development Table 104. ProMetic Life Sciences Company Information Table 105. ProMetic Life Sciences Business Overview Table 106. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 107. ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio Table 108. ProMetic Life Sciences Recent Development Table 109. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2021-2026) & (US$ Million) Table 110. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2027-2032) & (US$ Million) Table 111. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2021-2026) & (US$ Million) Table 112. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2027-2032) & (US$ Million) Table 113. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 114. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021-2026) & (US$ Million) Table 115. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (US$ Million) & (2027-2032) Table 116. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2021-2026) & (US$ Million) Table 117. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2027-2032) & (US$ Million) Table 118. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2021-2026) & (US$ Million) Table 119. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2027-2032) & (US$ Million) Table 120. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 121. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021-2026) & (US$ Million) Table 122. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (US$ Million) & (2027-2032) Table 123. China Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2021-2026) & (US$ Million) Table 124. China Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2027-2032) & (US$ Million) Table 125. China Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2021-2026) & (US$ Million) Table 126. China Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2027-2032) & (US$ Million) Table 127. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2021-2026) & (US$ Million) Table 128. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2027-2032) & (US$ Million) Table 129. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2021-2026) & (US$ Million) Table 130. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2027-2032) & (US$ Million) Table 131. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 132. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Region (US$ Million) & (2021-2026) Table 133. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Region (US$ Million) & (2027-2032) Table 134. SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2021-2026) & (US$ Million) Table 135. SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2027-2032) & (US$ Million) Table 136. SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2021-2026) & (US$ Million) Table 137. SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2027-2032) & (US$ Million) Table 138. SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 139. SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021-2026) & (US$ Million) Table 140. SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (US$ Million) & (2027-2032) Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. Alpha 1 Antitrypsin Deficiency Treatment Image Figure 2. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by Indication (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Augmentation Therapy Image Figure 5. Cystic Fibrosis(CF) Image Figure 6. Non-CF Bronchiectasis(NCFB) Image Figure 7. Diabetes Image Figure 8. Other Image Figure 9. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Growth Rate by End Users (US$ Million), 2021 VS 2025 VS 2032 Figure 10. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 11. COPD Image Figure 12. Cystic Fibrosis(CF) Image Figure 13. Non-CF Bronchiectasis(NCFB) Image Figure 14. Diabetes Image Figure 15. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size (US$ Million) & (2021-2032) Figure 16. Global Alpha 1 Antitrypsin Deficiency Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Alpha 1 Antitrypsin Deficiency Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Alpha 1 Antitrypsin Deficiency Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Indication (2021-2032) Figure 23. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2021 VS 2025 VS 2032) Figure 25. Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by End Users (2021-2032) Figure 26. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Type (2021-2032) Figure 28. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Application (2021-2032) Figure 29. North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Country (2021-2032) Figure 30. United States Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Type (2021-2032) Figure 35. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Application (2021-2032) Figure 36. Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Country (2021-2032) Figure 37. Germany Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Type (2021-2032) Figure 47. China Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Application (2021-2032) Figure 48. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Type (2021-2032) Figure 50. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Application (2021-2032) Figure 51. Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Region (2021-2032) Figure 52. Japan Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Type (2021-2032) Figure 60. SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Application (2021-2032) Figure 61. SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Country (2021-2032) Figure 62. Brazil Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Alpha 1 Antitrypsin Deficiency Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Augmentation Therapy
  • Cystic Fibrosis(CF)
  • Non-CF Bronchiectasis(NCFB)
  • Diabetes
  • Other
Applications
  • COPD
  • Cystic Fibrosis(CF)
  • Non-CF Bronchiectasis(NCFB)
  • Diabetes
Companies covered
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Boehringer Ingelheim
  • Teva Pharmaceutical Industries
  • Takeda
  • Baxter
  • Grifols
  • CSL Behring
  • Kamada Ltd
  • Chiesi Pharmaceuticals
  • Kedrion Group
  • Vertex Pharmaceuticals
  • ProMetic Life Sciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Alpha 1 Antitrypsin Deficiency Treatment Market by Indication
  3. 1.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Indication, 2021 VS 2025 VS 2032
  4. 1.2.2 Augmentation Therapy
  5. 1.2.3 Cystic Fibrosis(CF)
  6. 1.2.4 Non-CF Bronchiectasis(NCFB)
  7. 1.2.5 Diabetes
  8. 1.2.6 Other
  9. 1.3 Alpha 1 Antitrypsin Deficiency Treatment Market by End Users
  10. 1.3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by End Users, 2021 VS 2025 VS 2032
  11. 1.3.2 COPD
  12. 1.3.3 Cystic Fibrosis(CF)
  13. 1.3.4 Non-CF Bronchiectasis(NCFB)
  14. 1.3.5 Diabetes
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics
  1. 2.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends
  2. 2.2 Alpha 1 Antitrypsin Deficiency Treatment Industry Drivers
  3. 2.3 Alpha 1 Antitrypsin Deficiency Treatment Industry Opportunities and Challenges
  4. 2.4 Alpha 1 Antitrypsin Deficiency Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Perspective (2021-2032)
  2. 3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Growth Trends by Region
  3. 3.2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players
  2. 4.1.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Alpha 1 Antitrypsin Deficiency Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Alpha 1 Antitrypsin Deficiency Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Alpha 1 Antitrypsin Deficiency Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Alpha 1 Antitrypsin Deficiency Treatment Players, Product Type & Application
  8. 4.5 Global Alpha 1 Antitrypsin Deficiency Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market CR5 and HHI
  11. 4.6.3 2025 Alpha 1 Antitrypsin Deficiency Treatment Tier 1, Tier 2, and Tier 3
5 Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type
  1. 5.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Type (2021-2032)
6 Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application
  1. 6.1 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Alpha 1 Antitrypsin Deficiency Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Pfizer
  2. 7.1.1 Pfizer Company Information
  3. 7.1.2 Pfizer Business Overview
  4. 7.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  6. 7.1.5 Pfizer Recent Developments
  7. 7.2 GlaxoSmithKline
  8. 7.2.1 GlaxoSmithKline Company Information
  9. 7.2.2 GlaxoSmithKline Business Overview
  10. 7.2.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  12. 7.2.5 GlaxoSmithKline Recent Developments
  13. 7.3 AstraZeneca
  14. 7.3.1 AstraZeneca Company Information
  15. 7.3.2 AstraZeneca Business Overview
  16. 7.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  18. 7.3.5 AstraZeneca Recent Developments
  19. 7.4 Boehringer Ingelheim
  20. 7.4.1 Boehringer Ingelheim Company Information
  21. 7.4.2 Boehringer Ingelheim Business Overview
  22. 7.4.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  24. 7.4.5 Boehringer Ingelheim Recent Developments
  25. 7.5 Teva Pharmaceutical Industries
  26. 7.5.1 Teva Pharmaceutical Industries Company Information
  27. 7.5.2 Teva Pharmaceutical Industries Business Overview
  28. 7.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  30. 7.5.5 Teva Pharmaceutical Industries Recent Developments
  31. 7.6 Takeda
  32. 7.6.1 Takeda Company Information
  33. 7.6.2 Takeda Business Overview
  34. 7.6.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Takeda Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  36. 7.6.5 Takeda Recent Developments
  37. 7.7 Baxter
  38. 7.7.1 Baxter Company Information
  39. 7.7.2 Baxter Business Overview
  40. 7.7.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Baxter Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  42. 7.7.5 Baxter Recent Developments
  43. 7.8 Grifols
  44. 7.8.1 Grifols Company Information
  45. 7.8.2 Grifols Business Overview
  46. 7.8.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Grifols Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  48. 7.8.5 Grifols Recent Developments
  49. 7.9 CSL Behring
  50. 7.9.1 CSL Behring Company Information
  51. 7.9.2 CSL Behring Business Overview
  52. 7.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  54. 7.9.5 CSL Behring Recent Developments
  55. 7.10 Kamada Ltd
  56. 7.10.1 Kamada Ltd Company Information
  57. 7.10.2 Kamada Ltd Business Overview
  58. 7.10.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  60. 7.10.5 Kamada Ltd Recent Developments
  61. 7.11 Chiesi Pharmaceuticals
  62. 7.11.1 Chiesi Pharmaceuticals Company Information
  63. 7.11.2 Chiesi Pharmaceuticals Business Overview
  64. 7.11.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  66. 7.11.5 Chiesi Pharmaceuticals Recent Developments
  67. 7.12 Kedrion Group
  68. 7.12.1 Kedrion Group Company Information
  69. 7.12.2 Kedrion Group Business Overview
  70. 7.12.3 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Kedrion Group Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  72. 7.12.5 Kedrion Group Recent Developments
  73. 7.13 Vertex Pharmaceuticals
  74. 7.13.1 Vertex Pharmaceuticals Company Information
  75. 7.13.2 Vertex Pharmaceuticals Business Overview
  76. 7.13.3 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Vertex Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  78. 7.13.5 Vertex Pharmaceuticals Recent Developments
  79. 7.14 ProMetic Life Sciences
  80. 7.14.1 ProMetic Life Sciences Company Information
  81. 7.14.2 ProMetic Life Sciences Business Overview
  82. 7.14.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue and Gross Margin (2021-2026)
  83. 7.14.4 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Product Portfolio
  84. 7.14.5 ProMetic Life Sciences Recent Developments
8 North America
  1. 8.1 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue (2021-2032)
  2. 8.2 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2021-2032)
  3. 8.2.1 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2021-2026)
  4. 8.2.2 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2027-2032)
  5. 8.3 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Indication (2021-2032)
  6. 8.4 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2021-2032)
  7. 8.4.1 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2021-2026)
  8. 8.4.2 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2027-2032)
  9. 8.5 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by End Users (2021-2032)
  10. 8.6 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country
  11. 8.6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue (2021-2032)
  2. 9.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2021-2032)
  3. 9.2.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2021-2026)
  4. 9.2.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2027-2032)
  5. 9.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Indication (2021-2032)
  6. 9.4 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2021-2032)
  7. 9.4.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2021-2026)
  8. 9.4.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2027-2032)
  9. 9.5 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by End Users (2021-2032)
  10. 9.6 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country
  11. 9.6.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Alpha 1 Antitrypsin Deficiency Treatment Revenue (2021-2032)
  2. 10.2 China Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2021-2032)
  3. 10.2.1 China Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2021-2026)
  4. 10.2.2 China Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2027-2032)
  5. 10.3 China Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Indication (2021-2032)
  6. 10.4 China Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2021-2032)
  7. 10.4.1 China Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2021-2026)
  8. 10.4.2 China Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2027-2032)
  9. 10.5 China Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by End Users (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue (2021-2032)
  2. 11.2 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2021-2032)
  3. 11.2.1 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2021-2026)
  4. 11.2.2 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2027-2032)
  5. 11.3 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Indication (2021-2032)
  6. 11.4 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2021-2032)
  7. 11.4.1 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2021-2026)
  8. 11.4.2 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2027-2032)
  9. 11.5 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by End Users (2021-2032)
  10. 11.6 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country
  11. 11.6.1 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2021-2032)
  3. 12.2.1 SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2021-2026)
  4. 12.2.2 SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Indication (2027-2032)
  5. 12.3 SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by Indication (2021-2032)
  6. 12.4 SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2021-2032)
  7. 12.4.1 SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2021-2026)
  8. 12.4.2 SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue by End Users (2027-2032)
  9. 12.5 SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue Share by End Users (2021-2032)
  10. 12.6 SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country
  11. 12.6.1 SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Alpha 1 Antitrypsin Deficiency Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst